WO2009145489A3 - 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 - Google Patents

세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 Download PDF

Info

Publication number
WO2009145489A3
WO2009145489A3 PCT/KR2009/001726 KR2009001726W WO2009145489A3 WO 2009145489 A3 WO2009145489 A3 WO 2009145489A3 KR 2009001726 W KR2009001726 W KR 2009001726W WO 2009145489 A3 WO2009145489 A3 WO 2009145489A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
recombinant protein
same
permeable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001726
Other languages
English (en)
French (fr)
Other versions
WO2009145489A2 (ko
Inventor
조대웅
이종민
박경호
동민탐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procell Therapeutics Inc
Original Assignee
Procell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procell Therapeutics Inc filed Critical Procell Therapeutics Inc
Priority to US12/936,334 priority Critical patent/US8586544B2/en
Priority to EP09754954A priority patent/EP2270055A4/en
Publication of WO2009145489A2 publication Critical patent/WO2009145489A2/ko
Publication of WO2009145489A3 publication Critical patent/WO2009145489A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 혈관형성 억제인자(angiogenic inhibitor) 엔도스타틴(endostatin)에 거대분자 전달 도메인(macromolecule transduction domain, MTD)이 융합되어 세포투과성을 갖는 엔도스타틴 재조합 단백질, 상기 세포투과성 엔도스타틴 재조합 단백질을 코딩하는 폴리뉴클레오티드, 상기 세포투과성 엔도스타틴 재조합 단백질의 발현벡터, 및 상기 세포투과성 엔도스타틴 재조합 단백질을 유효성분으로 함유하는 암 혈관형성 억제활성이 강화된 항암제용 약학 조성물에 관한 것이다. 본 발명에 따른 세포투과성을 갖는 엔도스타틴 재조합 단백질은 혈관 형성 억제인자 엔도스타틴을 세포 내로 고효율로 도입하여 종양 조직 내에 존재하는 혈관내피세포의 이동, 증식, 침투, 튜브 형성 등을 억제하고 신생 미세혈관의 형성을 차단함으로써 우수한 항암 활성을 나타내므로, 다양한 암에 대한 항암제로서 유용하게 사용될 수 있다.
PCT/KR2009/001726 2008-04-04 2009-04-03 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 Ceased WO2009145489A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/936,334 US8586544B2 (en) 2008-04-04 2009-04-03 Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component
EP09754954A EP2270055A4 (en) 2008-04-04 2009-04-03 CELLPERMEABLE RECOMBINANT ENDOSTATINE PROTEIN, POLYNUCLEOTIDE FOR ITS CODING AND ANTICIPATED PREPARATION WITH THE PROTEIN AS AN ACTIVE SUBSTANCE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4231208P 2008-04-04 2008-04-04
US61/042,312 2008-04-04

Publications (2)

Publication Number Publication Date
WO2009145489A2 WO2009145489A2 (ko) 2009-12-03
WO2009145489A3 true WO2009145489A3 (ko) 2010-01-21

Family

ID=41377733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001726 Ceased WO2009145489A2 (ko) 2008-04-04 2009-04-03 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물

Country Status (4)

Country Link
US (1) US8586544B2 (ko)
EP (1) EP2270055A4 (ko)
KR (1) KR101263424B1 (ko)
WO (1) WO2009145489A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108291248B (zh) * 2011-09-09 2024-03-08 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体
EP2811281B1 (en) * 2012-01-31 2017-10-25 National Cancer Center Composition for aggregating biological sample, method for preparing paraffin block using same, and method for analysing paraffin blocks by microscopy
CN103992400B (zh) * 2014-05-29 2017-01-04 江苏吴中医药集团有限公司苏州中凯生物制药厂 重组人血管内皮抑素的复性液及其制备、使用方法
CN104407153B (zh) * 2014-12-03 2016-04-06 上海交通大学医学院附属上海儿童医学中心 Map2k1作为诊断动脉导管闭合或开放的标志物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029855A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof
WO1999062944A2 (en) * 1998-06-03 1999-12-09 The Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of using the same
US20020123458A1 (en) * 1995-10-23 2002-09-05 O'reilly Michael S. Endostatin protein and fragments thereof
WO2003102187A1 (en) * 2002-05-31 2003-12-11 Scegen Pty Ltd Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2029273A1 (en) * 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6174861B1 (en) * 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
US6852691B1 (en) * 1997-12-08 2005-02-08 Beth Israel Deaconess Medical Center Anti-angiogenic peptides and methods of use thereof
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CN100543036C (zh) * 2002-05-06 2009-09-23 得克萨斯州大学系统董事会 递送治疗或诊断试剂的导向蛋白质
US7078485B2 (en) * 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
EP2837636B1 (en) 2007-01-29 2018-04-11 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123458A1 (en) * 1995-10-23 2002-09-05 O'reilly Michael S. Endostatin protein and fragments thereof
WO1999029855A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof
WO1999062944A2 (en) * 1998-06-03 1999-12-09 The Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of using the same
WO2003102187A1 (en) * 2002-05-31 2003-12-11 Scegen Pty Ltd Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2270055A4 *

Also Published As

Publication number Publication date
US20110092441A1 (en) 2011-04-21
KR20110013365A (ko) 2011-02-09
EP2270055A4 (en) 2011-06-29
WO2009145489A2 (ko) 2009-12-03
KR101263424B1 (ko) 2013-05-14
EP2270055A2 (en) 2011-01-05
US8586544B2 (en) 2013-11-19

Similar Documents

Publication Publication Date Title
Su et al. Integrinβ-1 in disorders and cancers: molecular mechanisms and therapeutic targets
Toton et al. Beclin-1 and its role as a target for anticancer therapy
WO2009145489A3 (ko) 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
WO2009063970A1 (ja) 抗gpr49抗体を用いる癌の診断および治療
WO2010101627A3 (en) Methods and systems for treatment and/or diagnosis
WO2011069104A3 (en) Multispecific antibodies, antibody analogs, compositions, and methods
WO2010041913A3 (ko) Grs 단백질 또는 이의 단편의 신규한 용도
WO2010078517A3 (en) Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
UA115027C2 (uk) Cxcr2-зв'язуючі поліпептиди
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
MX2012011840A (es) Estructuras multimericas especificas para ligado inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trial).
EA201071300A1 (ru) Антитела к cxcr4
WO2014117050A3 (en) Modified mirna as a scaffold for shrna
HK1203528A1 (zh) 包含igg2鉸鏈結構域的融合蛋白
BRPI0915142A8 (pt) Polipeptídeos, ácido nucleico e usos dos mesmos
EP2592156A3 (en) Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
WO2008082889A3 (en) Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
SA520420426B1 (ar) مركبات ترابطية تستهدف إنتجرين واستخداماتها
WO2011053660A3 (en) Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors
WO2010056043A3 (en) Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same
WO2010031749A9 (en) Compositions and methods for detecting tlr3
Yu et al. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants
WO2011094430A3 (en) Pro-angiogenic fragments of prominin-1 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09754954

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009754954

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107022430

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12936334

Country of ref document: US